Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Takuya Oda; Hazumu Nagata; Yasutaka Nakashima; Etsuro Nanishi; Yui Takada; Manao Nishimura; Eiji Kubo; Ken Hatae; Shouichi Ohga

doi:10.1016/j.jpeds.2019.06.018

Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

J Pediatr. 2019 Nov:214:227-230. doi: 10.1016/j.jpeds.2019.06.018. Epub 2019 Jul 24.

Authors

Takuya Oda¹, Hazumu Nagata², Yasutaka Nakashima¹, Etsuro Nanishi³, Yui Takada¹, Manao Nishimura¹, Eiji Kubo¹, Ken Hatae¹, Shouichi Ohga³

Affiliations

¹ Department of Pediatrics, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
² Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: dadan@pediatr.med.kyushu-u.ac.jp.
³ Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

PMID: 31351682
DOI: 10.1016/j.jpeds.2019.06.018

Abstract

Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.

Keywords: concentration; fever duration; intravenous immunoglobulin; preparation; treatment-related adverse event.

Publication types

Comparative Study

MeSH terms

Child, Preschool
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Immunoglobulins, Intravenous / administration & dosage*
Immunologic Factors / administration & dosage
Infusions, Intravenous / statistics & numerical data
Male
Mucocutaneous Lymph Node Syndrome / drug therapy*
Retrospective Studies
Treatment Outcome

Substances

Immunoglobulins, Intravenous
Immunologic Factors